Hydrocortison Dexcel (Hydrocortisone)

Hydrocortison Dexcel is prescribed for several endocrine and inflammatory conditions where cortisol replacement or systemic glucocorticoid activity is required.

• Treatment of primary or secondary adrenal insufficiency, such as Addison’s disease.
• Management of congenital adrenal hyperplasia to suppress excess androgen production.
• Short‑term control of severe inflammatory or autoimmune disorders when oral glucocorticoids are indicated.
• Adjunct therapy for certain dermatologic or rheumatologic diseases that respond to systemic steroids.
• Replacement therapy during periods of physiological stress (e.g., surgery, infection) in patients with known cortisol deficiency.

• Hydrocortison Dexcel delivers hydrocortisone, which diffuses across cell membranes and binds to intracellular glucocorticoid receptors. The drug‑receptor complex translocates to the nucleus, where it interacts with glucocorticoid response elements on DNA, modulating transcription of anti‑inflammatory proteins and repressing pro‑inflammatory cytokines. This genomic effect reduces leukocyte migration, stabilizes lysosomal membranes, and decreases capillary permeability, producing both cortisol replacement and systemic immunosuppressive actions.

Like all systemic corticosteroids, Hydrocortison Dexcel may cause a range of adverse reactions that vary in frequency and severity.

Common

• Increased appetite and weight gain.
• Fluid retention causing mild swelling.
• Elevated blood glucose or worsening diabetes control.

Serious

• Severe hypertension or cardiovascular complications.
• Osteoporosis and increased fracture risk with long‑term therapy.
• Suppression of the adrenal axis leading to adrenal insufficiency if stopped suddenly.

Healthcare providers should evaluate several factors before initiating Hydrocortison Dexcel to minimize risks and ensure appropriate use.

• Assess for active infections; avoid use in uncontrolled bacterial, viral, or fungal infections.
• Screen for hypertension, diabetes, or osteoporosis, and monitor these conditions regularly.
• Taper the dose gradually when discontinuing long‑term therapy to prevent adrenal crisis.
• Use with caution in pregnant or breastfeeding women; benefits must outweigh potential risks.
• Evaluate potential psychiatric effects, especially in patients with a history of mood disorders.
• Adjust dosage in patients with hepatic or renal impairment as clearance may be altered.

Hydrocortison Dexcel can alter the pharmacokinetics or pharmacodynamics of several other medicines, requiring careful management.

Avoid

• Strong CYP3A4 inducers such as rifampin, phenytoin, or carbamazepine, which may reduce hydrocortisone exposure.
• Concurrent use of systemic anticoagulants (e.g., warfarin) without monitoring, as corticosteroids can enhance anticoagulant effects.

Use with caution

• Non‑steroidal anti‑inflammatory drugs (NSAIDs) because of increased risk of gastrointestinal ulceration.
• Antidiabetic agents, since glucocorticoids may raise blood glucose and require dose adjustments.
• Vaccines containing live attenuated organisms, due to possible reduced immune response.
• Other immunosuppressants (e.g., azathioprine, methotrexate) that may compound infection risk.